|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.75 USD | -0.45% |
|
-1.20% | -19.73% |
| 03/12 | Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 | MT |
| 21/11 | Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial | MT |
| Capitalization | 1.02TCr 867.25Cr 810.1Cr 762.21Cr 1.4TCr 92TCr 1.53TCr 9.46TCr 3.67TCr 43TCr 3.82TCr 3.74TCr 1,58600Cr | P/E ratio 2025 * |
18.8x | P/E ratio 2026 * | 12.6x |
|---|---|---|---|---|---|
| Enterprise value | 888.68Cr 757.07Cr 707.19Cr 665.37Cr 1.22TCr 80TCr 1.34TCr 8.25TCr 3.2TCr 38TCr 3.33TCr 3.26TCr 1,38400Cr | EV / Sales 2025 * |
2.8x | EV / Sales 2026 * | 2.42x |
| Free-Float |
99.12% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BioMarin Pharmaceutical Inc.
| 1 day | -0.51% | ||
| 1 week | -1.20% | ||
| Current month | -5.67% | ||
| 1 month | -4.63% | ||
| 3 months | -2.46% | ||
| 6 months | -7.89% | ||
| Current year | -19.73% |
| 1 week | 52.55 |  | 54.33 |
| 1 month | 51.99 | | 56.45 |
| Current year | 50.76 | | 73.51 |
| 1 year | 50.76 | | 73.51 |
| 3 years | 50.76 | | 117.77 |
| 5 years | 50.76 | | 117.77 |
| 10 years | 50.76 | | 131.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 01/12/2023 |
Brian Mueller
DFI | Director of Finance/CFO | 51 | 29/01/2020 |
Gregory Friberg
CTO | Chief Tech/Sci/R&D Officer | 51 | 30/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Randy Meier
CHM | Chairman | 65 | 01/12/2023 |
Willard Dere
BRD | Director/Board Member | 71 | 18/07/2016 |
Robert Hombach
BRD | Director/Board Member | 59 | 29/09/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.45% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.45% | -1.20% | -20.37% | -50.35% | 1.02TCr | |
| -1.27% | +2.65% | -0.48% | -0.68% | 7.66TCr | |
| +2.86% | -0.91% | -34.22% | -38.37% | 5.75TCr | |
| -2.24% | -4.93% | +29.50% | +225.99% | 5.38TCr | |
| +1.38% | +69.20% | +69.20% | +69.20% | 5.25TCr | |
| +0.71% | -4.44% | +11.54% | -40.38% | 2.53TCr | |
| -2.35% | -8.17% | +32.91% | +14.30% | 1.89TCr | |
| +1.85% | -8.93% | +123.04% | +164.19% | 1.84TCr | |
| -4.52% | -16.57% | +40.58% | +954.81% | 1.65TCr | |
| +1.03% | +1.66% | +170.55% | +719.93% | 1.43TCr | |
| Average | -0.31% | -2.42% | +42.22% | +201.86% | 3.44TCr | |
| Weighted average by Cap. | -0.12% | -0.76% | +27.01% | +120.07% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 316.97Cr 270.03Cr 252.24Cr 237.32Cr 436.92Cr 29TCr 477.33Cr 2.94TCr 1.14TCr 14TCr 1.19TCr 1.16TCr 49TCr | 339.25Cr 289.01Cr 269.97Cr 254.01Cr 467.64Cr 31TCr 510.88Cr 3.15TCr 1.22TCr 14TCr 1.27TCr 1.25TCr 53TCr |
| Net income | 55Cr 47Cr 44Cr 41Cr 76Cr 4.99TCr 83Cr 511.29Cr 198.33Cr 2.35TCr 206.55Cr 202.19Cr 8.57TCr | 83Cr 71Cr 66Cr 62Cr 114.54Cr 7.53TCr 125.13Cr 771.81Cr 299.38Cr 3.55TCr 311.79Cr 305.21Cr 13TCr |
| Net Debt | -129.33Cr -110.18Cr -102.92Cr -97Cr -178.28Cr -12TCr -194.76Cr -1.2TCr -465.97Cr -5.52TCr -485.28Cr -475.05Cr -20TCr | -197.31Cr -168.09Cr -157.01Cr -147.73Cr -271.98Cr -18TCr -297.13Cr -1.83TCr -710.89Cr -8.42TCr -740.35Cr -724.74Cr -31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 52.78 $ | -0.40% | 5,48,841 |
| 11/25/11 | 52.99 $ | -1.32% | 18,31,122 |
| 10/25/10 | 53.70 $ | -0.07% | 26,69,618 |
| 09/25/09 | 53.74 $ | +0.83% | 22,65,979 |
| 08/25/08 | 53.30 $ | -0.19% | 19,60,069 |
Delayed Quote Nasdaq, December 12, 2025 at 11:42 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMRN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition